Adherent cells from adipose or placenta tissues and use thereof in therapy

• US 8,529,888 B2
• Filed: 09/02/2008
• Issued: 09/10/2013
• Est. Priority Date: 09/19/2007
• Status: Active Grant

• Current Assignee: Pluri Biotech Limited
• Original Assignee: Pluristem Ltd. (Pluri Inc.)
• Inventors: Meiron, Moran, Toren, Amir, Ofir, Rachel, Aberman, Zami, Drori-Carmi, Nirit
• Primary Examiner(s): DRISCOLL, LORA E BARNHART
• Application Number:
  US12/678,756
• Publication Number:
  US 20100209403A1
• Time in Patent Office: 1,834 Days
• Field of Search: None
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/35 Fat tissue; Adipocytes; Stromal cells; Connective tissues adipose-derived stem cells A61K35/28; collagen A61K38/39
• CPC Class Codes: A61K 35/36 Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells islets of Langerhans A61K35/39
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed.

Claims

1. A method of treating ischemia peripheral arterial disease (PAD) in a subject in need of treatment for PAD, comprising:

administering to the subject a therapeutically effective amount of undifferentiated placenta-derived adherent stromal cells,

wherein the adherent stromal cells do not express CD34;

thereby treating the PAD.

2. The method of claim 1, wherein at least 10% of said cells are at a proliferative phase.

3. The method of claim 1, wherein said peripheral arterial disease (PAD) is critical limb ischemia (CLI).

4. The method of claim 1, wherein said cells are propagated in three-dimensional (3D) culturing conditions.

5. The method of claim 4, wherein said three-dimensional (3D) culturing conditions comprise a 3D bioreactor.

6. The method of claim 4, wherein said three-dimensional (3D) culturing conditions are effected under perfusion.

7. The method of claim 4, wherein said three-dimensional (3D) culturing conditions comprise an adherent material selected from the group consisting of a polystyrene, a polyester, and a polypropylene.

8. The method of claim 1, wherein culturing of said cells is effected for at least 3 days.

9. The method of claim 1, wherein culturing of said cells is effected until at least 10% of said cells are proliferating.

10. The method of claim 4, wherein said cells express a marker selected from the group consisting of CD73, CD90, CD29 and CD105.

11. The method of claim 4, wherein said cells do not express a marker selected from the group consisting of CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD14, CD19, and CD79.

12. The method of claim 6, wherein said perfusion rate is adjusted in order to maintain a constant glucose concentration in the culture medium.

13. The method of claim 12, wherein said constant glucose concentration is about 550 mg/L.

14. The method of claim 1, wherein said cells are propagated in two-dimensional (2D) culturing conditions.

15. The method of claim 14, wherein said cells express a marker selected from the group consisting of CD90, CD105, CD73 and CD29.